Phoenix Life Sciences International Receives Approval for Name Change, Symbol Change, and Completion of Consolidation of Busi...
November 02 2018 - 1:20PM
InvestorsHub NewsWire
Denver, CO -- November 02, 2018 -- InvestorsHub NewsWire -- Phoenix
Life Sciences International Limited (OTC:
PLSI) (“Phoenix Life”), an international adaptive healthcare
solutions company, today announced it has completed the last stages
the consolidation of businesses and received approval from the
Financial Industry Regulatory Authority (“FINRA”) of the corporate
action completing its name change and change of stock symbol.
Phoenix Life Sciences International Limited will now trade under
the stock symbol PLSI.
“After five years of planning and hard work, we could not be more
excited to have completed this consolidation to build a world
changing organization,” said Martin Tindall, CEO of Phoenix Life
Sciences International. “This marks the end of what has been a long
transitional period for our company and the beginning of a new
chapter of opportunity for Phoenix Life. We have made incredible
progress over the past months towards our goal of creating a truly
international healthcare organization. Our focus on creating global
supply of pharmaceutical and nutraceutical products derived from
medical cannabis and other botanical compounds targeted towards
treating patients across the world with a range of diseases makes
me truly proud.”
The company has recently announced some of the following
milestones:
Tindall continued, “Unlike other companies that are focused on
retail or limited markets, our vision is to bring cannabinoid-based
treatments to a global audience through government-supported
healthcare systems. Starting in the South Pacific, we plan to
create a comprehensive supply chain of cannabinoid-based
pharmaceutical products that healthcare systems across the world
can utilize to improve the health of their people.”
For more information about Phoenix Life, visit https://www.plsi.co/.
About Phoenix
Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive
healthcare solutions company. Our business is to advance research
and integrate programs and manufacturing of products that target
and treat diabetes, pain, cancer, and address psychological,
gastrointestinal, autoimmune, neurological and sleep disorders. We
strive to create partnerships and integrate these programs for
human health into communities worldwide as part of our Global
Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the “Companies”) may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
“plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”,
“expect”, “should”, “believe,” and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to, known and unknown risks,
uncertainties and other factors which could cause the Company’s
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in the Company’s filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to the Companies herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. The Companies disclaim any obligation to update
forward-looking statements contained in this press release, except
as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore
the products sold by Phoenix Life Sciences International are not
available on U.S.
LEGAL
DISCLOSURE
Phoenix Life Sciences International does not sell or distribute any
products in the United States that are in violation of the United
States Controlled Substances Act (US.CSA). This company does not
grow, sell, and distribute cannabis-based products in the United
States and is solely involved with the legal distribution of
medical cannabis-based products within certain international
markets outside of the United States.
Investor
Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
Media
Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From May 2023 to May 2024